Working... Menu

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03654716
Recruitment Status : Recruiting
First Posted : August 31, 2018
Last Update Posted : April 2, 2019
TeamConnor Childhood Cancer Foundation
Cookies for Kids' Cancer
Aileron Therapeutics
Information provided by (Responsible Party):
Steven DuBois, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 1, 2020
  Estimated Study Completion Date : June 1, 2022